Mechanostimulatory Platform for Improved CAR T Cell Immunotherapy

A Abed Al‐Kader Yassin (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) C Carlos Ureña Martin (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) G Guillaume Le Saux (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) A Ashish Pandey S Sivan Tzadka (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) E Esti Toledo (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) J Jatin Jawhir Pandit (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) T Tomer Sherf (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) I Idan Nusbaum (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) B Baisali Bhattachrya (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) R Rajashri Banerji (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) Y Yariv Greenshpan (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) M Muhammad Abu Abu Ahmad (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) O Olga Radinsky (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) M Menachem Sklartz (The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev) R Roi Gazit (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) M Moshe Elkabets (The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) S Saba Ghassemi (Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia) O Ofir Cohen (The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev) M Mark Schvartzman (Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel) A Angel Porgador (The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev)

Abstract

AbstractChimeric Antigen Receptor T (CAR T) cell immunotherapy has revolutionized cancer treatment, yet it is hindered by rapid T‐cell exhaustion caused by uncontrolled activation during CAR generation. Leveraging insights into T‐cell mechanosensing, a novel mechanostimulatory platform is engineered for T‐cell activation based on an antigen‐carrying surface with controlled elasticity and nanotopography. The platform is designed to optimize and balance T‐cell exhaustion, proliferation, and CAR expression. It enhances the differentiation of T cells into the central memory subset, which is crucial for the persistence of CAR T cell therapy's anticancer effects. The platform produces CAR T cells with higher antitumor efficacy, as validated through ex vivo experiments, and with higher in vivo persistence and ability to suppress tumor proliferation, as compared to CAR T cells generated by standard protocols. RNA‐seq analysis confirmed an increased transcriptional signature of central memory T cells. Furthermore, this platform completely eliminates T‐cell toxicity associated with the non‐viral transfection process typically observed with standard activation methods. This platform presents a promising pathway for improving the efficiency and safety of CAR T cell therapy.

Article Details

Volume / Issue Vol. 37, Issue 29
Published July 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (21)

A

Abed Al‐Kader Yassin

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

C

Carlos Ureña Martin

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

G

Guillaume Le Saux

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

A

Ashish Pandey

S

Sivan Tzadka

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

E

Esti Toledo

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

J

Jatin Jawhir Pandit

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

T

Tomer Sherf

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

I

Idan Nusbaum

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

B

Baisali Bhattachrya

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

R

Rajashri Banerji

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

Y

Yariv Greenshpan

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

M

Muhammad Abu Abu Ahmad

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

O

Olga Radinsky

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

M

Menachem Sklartz

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev

R

Roi Gazit

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

M

Moshe Elkabets

The Shraga Segal Department of Microbiology Immunology, and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

S

Saba Ghassemi

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia

O

Ofir Cohen

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev

M

Mark Schvartzman

Department of Materials Engineering Faculty of Engineering Ben‐Gurion University of the Negev Beer‐Sheva 8410501 Israel

A

Angel Porgador

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev